Tag: carcinoid clinical trials
STARTRK-2: A Basket Trial for Neuroendocrine Tumor Patients with Specific Gene Rearrangements
Precision medicine, molecular testing, basket studies, STARTRK-2 – it may sound like technology of the future but it is here today and it might be the answer to slowing or stopping tumor growth for neuroendocrine tumor (NET) patients who have specific…
READ MORE
Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial
Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…
READ MORE
DENIED: Michael Farris’ Journey with Insurance for Neuroendocrine Cancer Treatment
The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught…
READ MORE
Lexicon Pharmaceuticals, Inc. Continues Recruiting for Phase 3 Studies in Carcinoid Syndrome
Many patients face the challenge of controlling carcinoid syndrome which can persist even while being treated with somatostatin analog (SSA) therapy. For patients on SSA therapy who continue to experience conditions such as diarrhea, frequent bowel…
READ MORE
Clinical Trial for GI Carcinoid Patients Recruiting Through September
Gastrointestinal carcinoid patients who have tumors that either are not suitable for standard treatment or are not responding to standard treatment have the opportunity to enroll in a Phase I/II clinical trial conducted by Tekmira Pharmaceuticals…
READ MORE
Zebra Talk — A Handbook for Newly Diagnosed Carcinoid & Neuroendocrine Tumor Patients and Their Primary Care Physicians
There’s a terrific new resource for carcinoid and neuroendocrine tumor patients and their primary care physicians entitled Zebra Talk. According to Suzi Garber of Bucks County, Pennsylvania, editor, the handbook “is intended as a reference for those…
READ MORE
New England Carcinoid Connection Announces June 2014 Conference for the Carcinoid and Neuroendocrine Tumor Community
Carcinoid and neuroendocrine cancer patients, family members, caregivers, and healthcare professionals are invited to attend the New England Carcinoid Connection Conference on Friday, June 27, 2014 at The Lantana in Randolph, Massachusetts. The…
READ MORE
Gallium-68 Scan Coming to NOLANETS for Carcinoid and Neuroendocrine Tumor Patients
Dr. Eugene A. Woltering has announced that the Gallium-68 DOTATATE PET/CT scan is going to be available beginning in the summer of 2014 through The New Orleans Louisiana Neuroendocrine Tumor Specialists (NOLANETS) Neuroendocrine Tumor Program at …
READ MORE
First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate
Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …
READ MORE
FDA Approves Amendment for PRRT Clinical Trial in Texas
BREAKING NEWS: The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate…
READ MORE
